New shot could offer four months of HIV protection
NCT ID NCT06741397
Summary
This study is testing a new, longer-lasting version of an injectable HIV prevention medicine. It aims to see if getting a shot every four months keeps enough medicine in the body to block HIV infection, and checks how safe and tolerable it is. The study includes 229 adolescents and adults who are at risk of getting HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Birmingham, Alabama, 35222, United States
-
GSK Investigational Site
Los Angeles, California, 90027, United States
-
GSK Investigational Site
Los Angeles, California, 90035, United States
-
GSK Investigational Site
Los Angeles, California, 90036, United States
-
GSK Investigational Site
Los Angeles, California, 90069, United States
-
GSK Investigational Site
Palm Springs, California, 92262, United States
-
GSK Investigational Site
Doral, Florida, 33172, United States
-
GSK Investigational Site
Ft. Pierce, Florida, 34982, United States
-
GSK Investigational Site
Orlando, Florida, 32803, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33407, United States
-
GSK Investigational Site
Chicago, Illinois, 60612-7230, United States
-
GSK Investigational Site
New Orleans, Louisiana, 70112, United States
-
GSK Investigational Site
Springfield, Massachusetts, 01105, United States
-
GSK Investigational Site
Berkley, Michigan, 48072, United States
-
GSK Investigational Site
Kansas City, Missouri, 64111, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89119, United States
-
GSK Investigational Site
New York, New York, 10029, United States
-
GSK Investigational Site
Valhalla, New York, 10595, United States
-
GSK Investigational Site
Greensboro, North Carolina, 27401-1209, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45267, United States
-
GSK Investigational Site
Columbus, Ohio, 43210, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15212, United States
-
GSK Investigational Site
Dallas, Texas, 75246, United States
-
GSK Investigational Site
Fort Worth, Texas, 76104, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States
-
GSK Investigational Site
San Juan, 00909, Puerto Rico
-
GSK Investigational Site
San Juan, 909, Puerto Rico
Conditions
Explore the condition pages connected to this study.